Analysis of Thrombotic Events in Patients Receiving Ibrutinib
Researchers found a low incidence of thrombotic events in patients receiving ibrutinib, though some patients still experienced bleeding.
Thromboembolism
Expert Panel Releases Recommendations on Unmet Clinical Needs With Ph-Negative Myeloproliferative Neoplasms
An overview of the findings of an expert panel that examined the unmet clinical needs for patients with Ph-negative MPNs to assess for risks of thrombosis.
Guideline Update for Venous Thromboembolism Prophylaxis in Patients With Cancer
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
SAVED Tool Improves Assessment of Venous Thromboembolism Risk in Patients With Multiple Myeloma
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
Number of Comorbidities Linked to Risk of Thromboembolism in Leukemia, Lymphoma
A retrospective study sought to determine the risk factors for thromboembolism in patients with acute leukemia or lymphoma.
Cardiovascular, Thromboembolic Mortality Risk Factors in Multiple Myeloma
An analysis of SEER data identified the risk for these cardiovascular events and the common related causes of death among patients with MM.
Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years
A study presented at the 2018 ASCO Annual Meeting investigated the mortality risk for patients with multiple myeloma who develop VTE.
Platinum-Based Chemotherapies Demonstrate Similar Risk for Thromboembolic Events
Platinum-based chemotherapy agents for lung cancer may increase the risk for thromboembolism.
No Benefit to Extensive Cancer Screening in Unprovoked Venous Thromboembolism
Although unprovoked VTE may be a sign of occult cancer, results of a meta-analysis showed no benefit to extensive cancer screening in these patients.
Tissue Factor May Predict for Recurrent VTE in Patients Receiving Anticoagulants
An evaluation of the association of tissue factor, clinical risk factors, and other biomarkers measured at the time of initial VTE with recurrent VTE helps determine their predictive value for patients at high risk.
Next post in Side-Effect Management
